Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina

Vaccine

Volumn 29, Issue 31, 2011, Pages 4963-4972

  Urueña, Analía ^a   Pippo, Tomás ^a   Betelu, María Sol ^a   Virgilio, Federico ^a   Giglio, Norberto ^b   Gentile, Angela ^a   Jimenez, Salvador García ^c   Jáuregui, Bárbara ^d   Clark, Andrew D ^e   Diosque, Máximo ^a   Vizzotti, Carla ^a  

^a Ministerio de Salud de la Nación ^*  (United States)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c Representación de la Organización Panamericana de la Salud   (Argentina)

^d PAN AMERICAN HEALTH ORGANIZATION   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Argentina; Cost effectiveness; Pneumococcal conjugate vaccine

Indexed keywords

10 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 13 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARGENTINA; ARTICLE; BACTEREMIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; IMMUNIZATION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ARGENTINA; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; INFANT; INFANT, NEWBORN; MODELS, STATISTICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 79959739454     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.111     Document Type: Article

References (42)

1. Rudan I., Boschi-Pinto C., Biloglav Z., Mulholland K., Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008, 86(5 (May)).
2. Tregnaghi M., Ceballos A., Ruttimann R., Peeters P., Tregnaghi J.P., Ussher J., et al. Vigilancia epidemiológica activa de la enfermedad neumocócica en lactantes, en el ámbito ambulatorio y en la internación. Arch Argent Pediatr 2006, 104(1):3-10.
3. Tregnaghi M., Ceballos A., Ruttimann R., Peeters P., Tregnaghi J.P., Ussher J., et al. Active epidemiologic surveillance of pneumonia invasive pneumococcal disease in ambulatory hospitalized infants in Cordoba Argentina. Ped Infect Dis J 2006, 25(4):370-372.
4. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J., et al. Efficacy safety immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Ped Infect Dis J 2000, 19(3):187-195.
5. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Khol I., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomized double-blind efficacy study. Lancet 2006, 367(March):740-748.
6. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsène J.P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Ped Infect Dis J 2009, 28(April (4)):S66.
7. Bermal N., Szenborn L., Chrobot A., Alberto E., Lommel P., Gatchalian S., et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assesment of immunogenicity. Ped Infect Dis J 2009, 28(April (4)):S89.
8. Chevalier B., Vesikari T., Brzostek J., Knuf M., Bermal N., Aristegui J., et al. Safety and reactogenicity of the 10-valent Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Ped Infect Dis J 2009, 28(April (4)):S109.
9. Omeñaca F., Constantopoulos A., Merino J.M., Tejedor J.C., Athanasiadou F., Francois N., et al. Vaccination of preterm infants with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Ped Infect Dis J 2009, 28(June (6)):e190.
10. Esposito S., Tansey S., Thompson A., Ferrera G., Maida A., Bona G., et al. Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine given as a 3-dose series with routine vaccines in healthy children. Ped Infect Dis J 2009, 28(June (6)):e169.
11. Diez-Domingo J., Gurtman A., Bernaola E., Gimenez-Sanchez F., Martinon-Torres F., Pineda-Solas V., et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers receiving routine vaccination in Spain. Ped Infect Dis J 2009, 28(June (6)):e167.
12. Grimpel E., Laudat F., Baker S.A., Sekaran C., Gruber W.C., Scott D.A. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy children in France. Ped Infect Dis J 2009, 28(June (6)):e174.
13. Hughes J.Y., Snape M.D., Klinger C.L., Daniels E., Layton H., John T.M., et al. Immunogenicity of booster doses of 13-valent pneumococcal conjugate and HIB/MENC vaccines given at 12 months of age in the UK. Ped Infect Dis J 2009, 28(June (6)):e177.
14. Martinon-Torres F., Gimenez-Sanchez F., Gurtman A., Bernaola E., Diez-Domingo J., Carmona A., et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine given with meninigococcal C conjugate and other pediatric vaccinations in Spain. Ped Infect Dis J 2009, 28(June (6)):e185.
15. Reingold A., Hadler J., Farley M.M., Harrison L., Lynfield R., Bennett N., et al. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR 2008, 57(February (6)):144-148.
16. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N., Lynfield R., et al. Decline in invasive pneumococcal disease after introduction of protein-polysaccharide conjugate vaccine. NEJM 2003, 348(18):1737-1746.
17. Swanson D.S., Harrison C.J., Jackson M. Epidemiological trends in pediatric invasive pneumococcal disease. 48th Annual ICAAC/IDSA 46th Annual Meeting 2008.
18. De Wals P., Jetté L., Sevin E., Ouakki M., Douville-Fradet M., Markowski F., et al. Changes in the epidemiology of invasive pneumococcal disease (IPD) following implementation of a 7-valent pneumococcal conjugate vaccine (pcv7) program in Quebec, Canada. 48th Annual ICAAC/IDSA 46th Annual Meeting 2008.
19. Jacobs M.R., Good C.E., Bajaksouzian S., Windau A.R. Emergence of non-vaccine serotypes of streptococcus pneumoniae in Cleveland in relation to introduction of the protein conjugated pneumococcal vaccine. 48th Annual ICAAC/IDSA 46th Annual Meeting 2008.
20. Ampofo K., Osguthorpe R., Mason E.O., Daly J., Pavia A.T., Byington C.L., et al. Pneumococcal meningitis in Utah children: evolution of serotypes (1996-2008). 48th Annual ICAAC/IDSA 46th Annual Meeting 2008.
21. Gubbay J.B., Green K., Pong-Porter S., Low D.E., Mcgeer A. Impact of 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) in children in Toronto and peel regions, Ontario, Canada. 48th Annual ICAAC/IDSA 46th Annual Meeting 2008.
22. Vestrheim D.F., Aaberge I.S., Hoiby E.A., Caugant D.A. Replacement of pneumococcal serotypes among colonized children following introduction of PCV-7 in The Norwegian Vaccination Programme. Ped Infect Dis J 2009, 28(June (6)):e77.
23. Murray C.J.L., Lopez A.D. The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020 1996, Harvard University Press, Cambridge.
24. Ministerio de Salud de la Nación Argentina. Dirección de Estadísticas e Información de la Salud. Base de datos total país. Año 2005.
25. Teele D.W., Klein J., Rosner B. Epidemiology of otitis media during the first seven years of life in children in Greater Boston: a prospective cohort study. J Infect Dis 1989, 160(July (1)):83-94. and the Greater Boston Otitis Media Study Group.
26. Ruvinsky R., Gentile A., Gentile F., Gil C., Kupervaser J., Quiriconi M., et al. P1332 Surveillance of probably bacterial pneumonia in children less than 5 years old in two geographical areas in Argentina. Clin Microbiol Infect 2005, 11(Suppl. 2).
27. Bakir J., Gentile A., López Holtmann G., Procopio A., Vazquez M. Perfil epidemiológico de las infecciones invasivas por Streptococcus pneumoniae. Arch Argent Pediatr 2001, 99(2).
28. Meningoencefalitis Por Streptococcus pneumoniae en menores de 5 años. Casos y Tasas Acumulados por 100.000 habitantes hasta la 53° semana epidemiológica. PAIS ARGENTINA por Provincia. Años 2008-2008. Dirección de Epidemiología del Ministerio de Salud de la Nación.
29. Baraff L., Lee S.I., Schriger D.L. Outcomes of bacterial meningitis in children: a meta-analysis. Ped Infect Dis J 1993, 12(5):389-394.
30. Rowensztein H., Demirdjian G., Rodríguez J. Carga de enfermedad y costos asociados a las internaciones por infección respiratoria aguda en niños. Arch Argent Pediatr 2007, 105(1):5-11.
31. World Health Organization. WHO Guide for standardization of economic evaluations. WHO/IVB/08.14.
32. MERCOSUR/XXX N° 11/P. RES N° 06/09 "Directrices Metodológicas para Estudios de Evaluación Económica de Tecnologias Sanitarias" SGT N°11 - Montevideo, 09/X/09.
33. Hansen J., Black S., Shinefield H., Cherian T., Benson J., Fireman B., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia. Ped Infect Dis J 2002, 21(9):810-815.
34. Sociedad Argentina de Pediatría. Infecciones en Pediatría Ambulatoria. Otitis Media. http://www.sap.org.ar/staticfiles/educacion/consensos/pedamb/coniambo.htm.
35. Mahon B., Hsu K., Sudarani K., Kaplan S.L., Mason E.O., Pelton S.I. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 2006, 24:2514-2520.
36. The Burden of Pneumococcal Disease and Cost-Effectiveness of a Pneumococcal Vaccine in Latin America and the Caribbean. A Review of the Evidence and a Preliminary Economic Analysis. Sabin Vaccine Institute; 2007. http://www.sabin.org/.
37. Vespa G., Constenla D., Pepe C., Safadi M.A., Berezin E., Cássio de Morais J., et al. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Pub 2009, 26(6):518-528.
38. Sinha A., Constenla D., Valencia J.E., O'Loughlin R., Gomez E., De La Hoz F., et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Pub 2008, 24(5):304-313.
39. Giaccheto Larraz G., Telechea Ortiz H., Speranza Mourine N., Giglio N., Cane A., Pírez garcía M.C., et al. Cost-effectiveness of universal pneumococcal vaccination in Uruguay. Rev Panam Salud Pub 2010, 28(2):92-99.
40. Sartori A.M., De Soárez P.C., Novaes H.M. Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunization of infants in Brazil. J Epidemiol Community Health 2010, (September). [Ahead of print].
41. Giglio N.D., Cane A.D., Micone P., Gentile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine 2010, 28:2302-2310.
42. Jáuregui B., Sinha A., Clark A.D., Bolaños B.M., Resch S., Toscano C.M., et al. Strenthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: lessons learned by PAHO's ProVac Iniciative. Vaccine 2011, (29):1099-1106.